{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:11:34Z","timestamp":1694776294881},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Enzyme immunoassays for quantifying hepatitis C virus (HCV) core antigen (Ag) have been proposed as an alternative to HCV RNA detection. The present study aimed to investigate the early kinetics of serum HCVcAg and its usefulness in predicting virological responses.<\/jats:p>\n            <jats:p>The clinical data of 135 patients with chronic hepatitis C treated with pegylated interferon alpha (PEG-IFN-\u03b1) and ribavirin was retrospectively collected. The patients were grouped according to their treatment outcomes as follows: sustained virological response (SVR), nonsustained virological response (N-SVR), and relapse.<\/jats:p>\n            <jats:p>Higher HCVcAg and HCV RNA levels were observed in patients in the N-SVR group than in the other groups at baseline. HCVcAg better predicted rapid virological response (RVR) compared with HCV RNA and had a predictive value similar to that of HCV RNA for SVR and early virological response. In the relapse group, HCV RNA decreased to 0 after 48 weeks, whereas HCVcAg was still detectable, indicating that HCVcAg more sensitively predicted relapse in antiviral therapy than HCV RNA.<\/jats:p>\n            <jats:p>For patients treated with PEG-INF-\u03b1 and ribavirin, HCVcAg may more sensitively predict relapse than HCV RNA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014795","type":"journal-article","created":{"date-parts":[[2019,3,10]],"date-time":"2019-03-10T12:11:06Z","timestamp":1552219866000},"page":"e14795","source":"Crossref","is-referenced-by-count":3,"title":["HCV core antigen is a useful predictor during pegylated-interferon\/ribavirin therapy in patients with hepatitis C virus genotype 1b"],"prefix":"10.1097","volume":"98","author":[{"given":"Zhijuan","family":"Fan","sequence":"first","affiliation":[{"name":"Clinical Laboratory of Tianjin Third Central Hospital"},{"name":"Tianjin Key Laboratory of Artificial Cell"},{"name":"Artificial Cell Engineering Technology Research Center of Public Health Ministry, Hedong District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, TEDA International Cardiovascular Hospital, Chinese Academy of Medical Science and Beijing Union Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Artificial Cell"},{"name":"Artificial Cell Engineering Technology Research Center of Public Health Ministry, Hedong District"},{"name":"Tianjin Institute of Hepatobiliary Disease, Hedong District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingmin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Tianjin TEDA Hospital, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Ding","sequence":"additional","affiliation":[{"name":"Clinical Laboratory of Tianjin Third Central Hospital"},{"name":"Tianjin Key Laboratory of Artificial Cell"},{"name":"Artificial Cell Engineering Technology Research Center of Public Health Ministry, Hedong District"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuye","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Laboratory of Tianjin Third Central Hospital"},{"name":"Tianjin Key Laboratory of Artificial Cell"},{"name":"Artificial Cell Engineering Technology Research Center of Public Health Ministry, Hedong District"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1600-6143.2008.02174.x","article-title":"Liver and intestine transplantation in the United States, 1997-2006","volume":"8","author":"Freeman","year":"2008","journal-title":"Am J Transplant"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12072-012-9342-y","article-title":"APASL consensus statements and management algorithms for hepatitis C virus infection","volume":"6","author":"Omata","year":"2012","journal-title":"Hepatol Int"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1478-3231.2009.02188.x","article-title":"The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report","volume":"30","author":"Antaki","year":"2010","journal-title":"Liver Int"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bjid.2012.10.028","article-title":"Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?","volume":"17","author":"Chakravarti","year":"2013","journal-title":"Braz J Infect Dis"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7754\/Clin.Lab.2013.130634","article-title":"HCV antigen testing for the diagnosis of hepatitis C infection: a cost-efficient algorithm","volume":"60","author":"Kadkhoda","year":"2014","journal-title":"Clin Lab"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0973-6247.126683","article-title":"Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays","volume":"8","author":"Gupta","year":"2014","journal-title":"Asian J Transfus Sci"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jcv.2010.02.012","article-title":"Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients","volume":"48","author":"Miedouge","year":"2010","journal-title":"J Clin Virol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.3748\/wjg.v20.i22.6701","article-title":"Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment","volume":"20","author":"Tillmann","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0255-0857(21)02232-5","article-title":"Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection","volume":"25","author":"Daniel","year":"2007","journal-title":"Indian J Med Microbiol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1128\/JCM.01856-09","article-title":"New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification","volume":"48","author":"Park","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/rmv.717","article-title":"Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up?","volume":"22","author":"Hosseini-Moghaddam","year":"2012","journal-title":"Rev Med Virol"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/JCM.06503-11","article-title":"Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients","volume":"50","author":"Descamps","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcv.2015.06.002","article-title":"The clinical significance of HCV core antigen detection during Telaprevir\/Peg-Interferon\/Ribavirin therapy in patients with HCV 1 genotype infection","volume":"69","author":"Garbuglia","year":"2015","journal-title":"J Clin Virol"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-230X-14-47","article-title":"Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection","volume":"14","author":"Feng","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection","volume":"55","author":"Craxi","year":"2011","journal-title":"J Hepatol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/1743-422X-8-364","article-title":"Expression of core antigen of HCV genotype 3a and its evaluation as screening agent for HCV infection in Pakistan","volume":"8","author":"Yousaf","year":"2011","journal-title":"Virol J"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1751-2980.2011.00496.x","article-title":"Evaluation of three different hepatitis C virus typing methods for detection of mixed-genotype infections","volume":"12","author":"Idrees","year":"2011","journal-title":"J Dig Dis"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.5897\/AJMR2012.2300","article-title":"Correlation between architect hepatitis C virus (HCV) core antigen and HCV ribonucleic acid levels in anti-HCV reactive patients in Turkey","volume":"7","author":"Buruk","year":"2013","journal-title":"Afr J Microbiol Res"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(02)11463-2","article-title":"Alternatives to nucleic acid testing in the blood transfusion service","volume":"360","author":"Laperche","year":"2002","journal-title":"Lancet"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jcv.2011.05.003","article-title":"Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay","volume":"51","author":"Medici","year":"2011","journal-title":"J Clin Virol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jcv.2013.08.028","article-title":"Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples","volume":"58","author":"Ottiger","year":"2013","journal-title":"J Clin Virol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/JCM.05175-11","article-title":"Is hepatitis C virus core antigen an adequate marker for community screening?","volume":"50","author":"Kuo","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R27-20230914","first-page":"2240","article-title":"Significance of the hepatitis C virus core antigen testing as an alternate marker for hepatitis diagnosis in Egyptian patients","volume":"19","author":"Soliman","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1128\/JVI.78.11.5867-5874.2004","article-title":"Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C","volume":"78","author":"Pham","year":"2004","journal-title":"J Virol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201903080-00064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:10:46Z","timestamp":1694718646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201903080-00064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014795","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}